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Abstract Oncotype DX testing is reimbursed in Israel for
node-negative and node-positive (N1?; up to 3 positive
nodes including micrometastases), estrogen receptor posi-
tive (ER?), breast cancer patients. This retrospective study
evaluated the impact of Oncotype DX testing on treatment
decisions in N1?/ER? breast cancer patients. To this end,
we compared treatments for all N? patients for whom
testing had been ordered with treatments for patients with
similar characteristics where the test had not been avail-
able. The retrospective analysis included 951 patients (282
Oncotype DX, 669 controls), all of whom received endo-
crine therapy with or without chemotherapy. In Oncotype
DX patients, 7.1, 37.0, and 100 % of those with low,
intermediate, and high Recurrence Score results (Oncotype
DX summary score) received chemotherapy, respectively
(P \ 0.0001, all comparisons). Chemotherapy use was
lower in Oncotype DX patients versus controls (24.5 vs.
70.1 %). In a multivariate logistic regression analysis in
which the probability of receiving chemotherapy was
modeled as a function of Oncotype DX testing, age, tumor
size, tumor grade, nodal status, and the interactions
between Oncotype DX testing and the other covariates,
Oncotype DX testing was associated with significantly
lower odds of receiving chemotherapy (odds ratio 0.16;
95 % CI 0.11–0.24; P \ 0.0001). In summary, our findings
suggest that Oncotype DX testing has a significant impact
on reducing chemotherapy use in N1?/ER? breast cancer
patients in Israel.
Keywords Adjuvant chemotherapy  Breast cancer 
Decision-making  Node positive  Oncotype DX 
Recurrence Score
Introduction
The St. Gallen Consensus Conference 2011 reflected a
transition to the predominance of tumor biology rather
than anatomical disease indicators (e.g., tumor size, extent
of nodal involvement) for clinical decision-making in
breast cancer (BC) [1]. Notably, the majority of the
panelists at the St. Gallen Consensus Conference did not
consider nodal involvement (up to 3 positive axillary
lymph nodes) as a sufficient reason for giving adjuvant
chemotherapy, whereas they did consider high grade
(grade 3), human epidermal growth factor receptor 2
S. M. Stemmer (&)  S. Rizel
Institute of Oncology, Davidoff Center, Rabin Medical Center,
Petah Tikva, Affiliated with the Sackler Faculty of Medicine,
39 Jabotinski St., Petah Tikva, Israel
e-mail: stemmer@post.tau.ac.il
S. H. Klang  S. Merling  N. Lieberman
Clalit Health Services, 101 Arlozorov St., Tel Aviv, Israel
N. Ben-Baruch
Kaplan Medical Center, Pasternak St, P.O.B 1, Rehovot, Israel
D. B. Geffen
Soroka University Medical Center and Ben-Gurion University
of the Negev, Reger St., Be’er Sheva, Israel
M. Steiner
Carmel Hospital, 7 Michal St., Haifa, Israel
L. Soussan-Gutman
Teva Pharmaceutical Industries Ltd, 12 Hatrufa St.,
Sapir Industrial Area, Netanya, Israel
C. Svedman
Genomic Health Inc, 301 Penobscot Drive, Redwood City, CA,
USA
123
Breast Cancer Res Treat (2013) 140:83–92
DOI 10.1007/s10549-013-2603-1
(HER2) overexpression, and having a ‘‘triple negative’’
disease [i.e., lack of expression of the estrogen receptor
(ER), progesterone receptor (PR), and HER2] as sufficient
reasons for such a treatment [1]. The panel at the con-
ference agreed that the summary risk score (Recurrence
Score, a numeric score between 0 and 100) derived from
the 21-gene reverse transcriptase-polymerase chain reac-
tion Oncotype DX assay (Genomic Health, Inc., Red-
wood City, CA) may be useful for making adjuvant
treatment decisions for ER? patients in whom uncertainty
remains after considering other factors (e.g., grade, HER2
status, etc.) [1]. The Recurrence Score as a predictor of
likely benefit of chemotherapy has also been acknowl-
edged by the American Society of Clinical Oncology [2],
the National Comprehensive Cancer Network [3], and the
European Society for Medical Oncology [4].
The Oncotype DX assay was validated (level I, category
B evidence [5]) to quantify the risk of distant recurrence in
tamoxifen-treated node-negative ER? BC patients and to
predict the benefit of chemotherapy in these patients [6–9].
Subsequently, the Recurrence Score has been demonstrated
to also be a prognosticator as a well as a predictor of the
benefit of chemotherapy in node-positive (N?) ER? BC
patients treated with endocrine therapy [10–13]. The
ongoing randomized phase 3 SWOG S1007 trial will
determine the effect of chemotherapy plus endocrine
therapy versus endocrine therapy alone in N? hormone
receptor positive BC patients with Recurrence Score B25
and will therefore provide insights into the interaction
between treatment received, clinical outcome, and the
continuous Recurrence Score value for patients within this
score interval [14].
In Israel, the Oncotype DX assay is widely used and is
reimbursed by all health-care organizations. Clalit Health
Services (CHS), Israel’s largest health-care organization
with 3.6 million members, approved Oncotype DX reim-
bursement for node-negative ER? BC patients in February
2006 and extended its reimbursement policy in January
2008 to include reimbursement for both node-negative and
N1? (up to 3 positive axillary lymph nodes including
micrometastases) ER? BC patients.
The impact of the Oncotype DX assay on clinical
practice has been evaluated in several studies in node-
negative ER? BC patients [15–27]; however data on the
impact of the Oncotype DX assay on treatment recom-
mendations in N? ER? BC patients are limited [25–29].
The current study was designed to evaluate the impact of
the Recurrence Score results on treatment decisions in
N1? ER? HER2 negative BC patients and to compare
treatment decisions in this patient group with those in a
control group comprised of patients in whom treatment




The study was approved by the institutional review boards
of the participating institutions.
This retrospective study compared treatment decisions
in 2 patient groups. The first group (‘‘Oncotype DX’’)
included all patients with N1?, ER?, HER2 negative, BC
patients who were diagnosed and had the Oncotype DX
assay between 2006 and 2009 through CHS. The second
group (controls) was identified by reviewing all patients
treated in the participating medical centers and including
patients (diagnosed between 2000 and 2010) for whom
treatment decisions were based on clinicopathologic
parameters alone and whose baseline characteristics were
similar to those in the ‘‘Oncotype DX’’ group.
Data source
For the Oncotype DX group, researchers collected infor-
mation from patients’ files on relevant biological data and
the treatments received. For the control group, relevant
information was collected from the medical records of
relevant patients treated in 4 medical centers in Israel
(Institute of Oncology-Davidoff Center, Kaplan Medical
Center, Lin Medical Center, and Soroka University Medi-
cal Center).
Statistical analysis
Descriptive statistics were used to summarize patient and
tumor characteristics and treatment received. Fisher’s exact
test was used in pairwise comparisons of chemotherapy
treatment percentages among the Recurrence Score groups.
Logistic regression analyses were used to compare the
probability of treatment between the Oncotype DX group
and the control group (including age group, tumor size,
tumor grade, and nodal status as covariates).
Results
A total of 951 patients were included in the analysis (282
Oncotype DX, 669 controls; Table 1). The vast majority of
the Oncotype DX patients (272 patients, 96.4 %) were
diagnosed from 2008 onward, whereas the vast majority of
the controls (588 patients, 87.9 %) were diagnosed prior to
2008. The groups were unbalanced with respect to tumor
size, tumor grade, and nodal status, with the clinical and
pathological characteristics of the control group associated
with more chemotherapy use compared with those of the
Oncotype DX group (i.e., larger tumors, higher proportion
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of patients with grade 3 tumors, and higher proportions of
patients with 1, 2, and 3 positive nodes; Table 1).
Recurrence Score outcomes and clinicopathologic
characteristics
In the Oncotype DX group, the mean Recurrence Score
(SD) result was 18.2 (9.2) with a range of 0–58. Of the 282
patients in the Oncotype DX group, 156 patients (55.3 %)
had a low Recurrence Score result (\18), 108 patients
(38.3 %) had an intermediate Recurrence Score result
(18–30), and 18 patients (6.4 %) had a high Recurrence
Score result (C31) (Table 2). The distributions of age,
tumor size, tumor grade, and nodal status in the 3 catego-
ries are shown in Table 2. The Recurrence Score result was
significantly associated with tumor grade, with higher
Recurrence Score results associated with higher histologic
grade (Spearman correlation; P = 0.0001) and there was a
trend toward significance with tumor size (higher
Recurrence Score results associated with larger tumors,
Spearman correlation; P = 0.054).
Recurrence Score outcomes and treatments received
(all patients)
All patients in the Oncotype DX and control groups
received endocrine therapy with or without chemotherapy
and none received biologic therapy. Overall, the use of
adjuvant chemotherapy was lower in the Oncotype DX
group compared with controls [24.5 vs. 70.1 %; adjusted
odds ratio (OR), 0.16; 95 % Wald confidence limits,
0.11–0.24; adjusted for age, tumor size, grade, and nodal
status]. The main source of this observed difference was
the very low use of adjuvant chemotherapy in the low
Recurrence Score group and the moderate use of adjuvant
chemotherapy in the intermediate Recurrence Score group
(7.1 and 37.0 %, respectively; Table 3). All patients in the
high Recurrence Score group were treated with chemo-
therapy. The differences in the proportions of patients
receiving chemotherapy between the low, intermediate,
and high Recurrence Score groups were statistically sig-
nificant (P \ 0.0001 for all pairwise comparisons).
Recurrence Score outcomes and treatments received:
subanalysis by tumor size, grade, and nodal status
Treatments received were also analyzed by subgroups
including age (B55 and[55 years of age), tumor size (\1,
1–2, and[2 cm), tumor grade (grade 1–3), and nodal status
(micrometastases and 1, 2, and 3 positive nodes). In all
subgroups analyzed, all high Recurrence Score patients
received chemotherapy, and a higher proportion of inter-
mediate Recurrence Score patients received chemotherapy
compared with low Recurrence Score patients (Fig. 1).
Furthermore, in all subgroups analyzed, the overall pro-
portion of Oncotype DX patients receiving chemotherapy
was lower compared with controls (Fig. 1). However, since
the Oncotype DX and the control groups were unbalanced
with respect to baseline characteristics associated with
chemotherapy use (i.e., tumor size, tumor grade, and nodal
involvement; Table 1), we performed a multivariate
logistic regression analysis (adjusting for these variables)
to assess the statistical significance of the observed dif-
ference in chemotherapy use between these 2 patient
groups.
Chemotherapy use in the Oncotype DX and control
groups: multivariate logistic regression analyses
We modeled the probability of receiving adjuvant che-
motherapy (using multivariate logistic regression on the
entire cohort) as a function of having Oncotype DX testing
Table 1 Baseline patient and tumor characteristics
Oncotype DX group Controls
N = 282 N = 669
Age
Median (range), years 61.5 (36–87) 59.0 (24–93)
Age categorya, N (%)
\40 years 6 (2.1) 34 (5.1)
40–55 years 88 (31.2) 224 (33.5)
[55 years 188 (66.7) 411 (61.4)
Tumor sizeb
Mean (SD)c, cm 1.87 (1.0) 2.1 (1.0)
Median (range), cm 1.6 (up to 6.5) 1.9 (up to 6)
Tumor grade categoryb,d, N (%)
Grade 1 40 (14.2) 75 (11.2)
Grade 2 155 (55.0) 323 (48.0)
Grade 3 46 (16.3) 194 (29.0)
Not applicable/unknown 41 (14.5) 77 (11.5)
Nodal involvemente, N (%)
Micrometastases 135 (47.9) 82 (12.3)
1 positive node 101 (35.8) 338 (50.5)
2 positive nodes 38 (13.5) 160 (23.9)
3 positive nodes 8 (2.8) 89 (13.3)
SD standard deviation
a P = 0.069 (comparing age distribution; v2 test)
b In cases of multicentric or bilateral disease, the largest tumor and
the highest grade were considered for the analysis; tumor size
information was not available for 3 patients in the intermediate
Recurrence Score group
c P = 0.0005 (Mann–Whitney test)
d P = 0.0001 (comparing tumor grade distribution; v2 test)
e P \ 0.0001 (comparing nodal status distribution; v2 test)
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(yes/no), age group (\40, 40–55, and [55 years), tumor
size (\1, 1–2, and, [2 cm), tumor grade (grade 1–3),
number of positive nodes (micrometastases, and 1, 2, and 3
positive nodes), as well as the interactions between testing
and each of the other covariates (these interactions were
found to be non-significant). Patients with missing data on
any covariate were excluded. Patients who underwent
Oncotype DX testing had significantly lower odds of
receiving chemotherapy compared with control patients
who were not tested (OR 0.16; P \ 0.0001), as were
patients [55 years of age (vs. patients \40 and
40–55 years of age), patients with grade 1 tumors (vs.
patients with grades 2 and 3 tumors), and patients with
micrometastases (vs. patients with 1, 2, and 3 positive
nodes) (Table 4). The odds of receiving chemotherapy
were similar for patients with 1 and 2 positive nodes;
however, patients with 3 positive nodes had significantly
increased odds of receiving chemotherapy compared with
those with either 1 or 2 positive nodes (P \ 0.005)
(Table 4).
Table 2 Distribution of age,
tumor size, tumor grade, and
nodal status by Recurrence
Score categories in the
Oncotype DX group
a Tumor size information was










n = 156 n = 108 n = 18
All (N = 282)
Age
Median (range), year 62 (39–87) 60 (36–78) 62.5 (38–73)
Age category, n
\40 (n = 6) 2 2 2
40–55 (n = 88) 49 34 5
[55 (n = 188) 105 72 11
Tumor sizea, mean (SD), cm 1.7 (0.8) 2.0 (1.2) 2.3 (1.2)
Tumor grade category, n
Grade 1 (n = 40) 34 6 0
Grade 2 (n = 155) 93 55 7














3 positive nodes (n = 8) 3 4 1
Table 3 Adjuvant treatment received by Recurrence Score category
Oncotype DX group Controls
Recurrence Score
Lowa (\18) Intermediatea (18–30) Higha (C31) Allb Allb
N = 282 N = 669n = 156 n = 108 n = 18
Treatment No. % No. % No. % No. % No. %
Chemotherapy plus endocrine therapy 11 7.1 40 37.0 18 100.0 69 24.5 469 70.1
Endocrine therapy 145 92.9 68 63.0 0 0.0 213 75.5 200 29.9
a P \ 0.0001 for comparing proportions of patients receiving chemotherapy between the low, intermediate, and high Recurrence Score groups
(all comparisons)
b Adjusted odds ratio for receiving chemotherapy in Oncotype DX patients versus controls, 0.16; 95 % Wald confidence limits, 0.11–0.24;
adjusted for age, tumor size, grade, and nodal status
86 Breast Cancer Res Treat (2013) 140:83–92
123
Fig. 1 Proportions of patients
receiving chemotherapy by
Recurrence Score category and
age group (a), tumor size (b),
grade (c), and nodal status (d).
Int intermediate, micromets
micrometastases, y year. Only 6
patients were \40 years of age;
tumor size information was not
available for 3 patients in the
intermediate Recurrence Score
group; grade information was
not applicable/not available for
41 patients in the Oncotype DX
group and 77 controls. In cases
of multicentric or bilateral
disease, the largest tumor and
the highest grade were
considered for the analysis
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A second multivariate logistic regression analysis was
performed for each of the age groups separately (Table 5).
Since the group of patients \40 years of age included
only 6 Oncotype DX patients, no reliable conclusions
could be drawn. For the 2 remaining age groups
(40–55 years of age and[55 years of age), the probability
of receiving adjuvant chemotherapy was modeled as a
function of tumor size (\1, 1–2, and [2 cm), tumor grade
(grade 1–3), number of positive nodes (micrometastases,
1, 2, or 3 positive nodes), and the interactions between
testing and each of the other covariates (these interactions
were found to be non-significant). In both age groups,
Oncotype DX testing was associated with significantly
lower odds of receiving chemotherapy, although the effect
was more pronounced in patients aged 40–55 years
compared with those aged [55 years (ORs 0.067 and
0.24, respectively; P \ 0.0001 for both). In the younger
patient group, tumor grade had a significant impact on the
odds of receiving chemotherapy, whereas in the older
patient group, both tumor grade and nodal status had a
significant impact on the odds of receiving chemotherapy
(Table 5).
Discussion
The current study suggests that Oncotype DX testing has a
significant impact on oncologists’ decision to treat
N1? ER? BC patients with chemotherapy. The use of
Oncotype DX testing was associated with a reduction in the
use of chemotherapy in this patient population by 65 %
Fig. 1 continued
Table 4 Odds ratios for receiving chemotherapy (logistic regression










40–55 vs. \40 years 1.15 0.42–3.16 0.78
[55 vs. \40 years 0.27 0.10–0.72 0.0088
[55 vs. 40–55 years 0.24 0.16–0.34 <0.0001
Tumor size
1–2 vs. \1 cm 0.46 0.25–0.83 0.0095
[2 vs. \1 cm 0.64 0.35–1.15 0.14
[2 vs. 1–2 cm 1.40 0.98–1.98 0.063
Tumor grade
Grade 2 vs. 1 1.76 1.08–2.85 0.023
Grade 3 vs. 1 3.88 2.21–6.79 <0.0001
Grade 3 vs. 2 2.21 1.47–3.30 0.0001
Nodal status
1 positive node vs.
micrometastases
1.66 1.05–2.63 0.029
2 positive nodes vs.
micrometastases
1.91 1.12–3.24 0.017
3 positive nodes vs.
micrometastases
7.29 3.36–15.84 <0.0001
2 vs. 1 positive nodes 1.15 0.76–1.75 0. 52
3 vs. 1 positive nodes 4.38 2.17–8.86 <0.0001
3 vs. 2 positive nodes 3.82 1.81–8.08 0.0004
A total of 118 patients were excluded from the analysis due to missing data
a Interactions between Oncotype DX testing and each of the other covari-
ates were found to be non-significant
Bold values represents statistically significant odds ratios
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(with an adjusted OR of 0.16). All patients with high
Recurrence Score results were treated with chemotherapy,
whereas those with low Recurrence Score results rarely
received chemotherapy.
Our findings, based on recent treatment patterns in
N1? ER? BC patients in Israel, are consistent with find-
ings from studies in node-negative populations around the
world. These studies demonstrated that in 19–44 % of
evaluated cases, recommendations for adjuvant treatment
were changed after receiving the Recurrence Score results
[15–27]. Of the patients for whom treatment recommen-
dations were changed, the most frequent change was from
chemotherapy plus endocrine therapy to endocrine therapy
alone (52–89 % of cases); however, a clinically relevant
proportion of patients were identified as likely to derive a
significant benefit from the addition of chemotherapy
[15–18, 20, 21, 23–26].
The current study is also consistent with the limited
available data on the impact of the Recurrence Score
results on treatment recommendations in the N? ER? BC
patient population [25–29]. For example, in a recent anal-
ysis, in which treatment recommendations pre- and post-
knowledge of Recurrence Score results were analyzed for a
mixed patient population of whom only 15 % were N?,
knowing the Recurrence Score results led to a 25 % overall
change in treatment recommendations (up to 89 % of these
changes were from chemotherapy plus endocrine therapy
to endocrine therapy alone) [28]. Furthermore, in a recent
physician survey, in which 160 medical oncologists in the
United States provided information on their most recent
N? ER? BC patient, 51 % of the medical oncologists
changed their treatment recommendations after obtaining
the Recurrence Score result, with the most frequent change
(65 % of cases) being from chemotherapy plus endocrine
therapy to endocrine therapy alone [29]. Our study is also
consistent with a recent prospective study in Germany that
showed a treatment recommendation change in 38.5 % of
122 evaluated N? ER? BC patients, with the most fre-
quent change (72 % of cases) being from chemotherapy
plus endocrine therapy to endocrine therapy alone [27].
Interestingly, our logistic regression analysis showed
that the impact of Oncotype DX testing on reducing the
odds of receiving chemotherapy was more pronounced in
patients aged 40–55 years, than in patients [55 years of
age, suggesting that in older patients, in whom chemo-
therapy treatment was less common overall, Oncotype DX
testing had a lower impact on changing treatment deci-
sions. These findings provide insight into the decision-
making process in the molecular profiling era by high-
lighting the patient populations for whom oncologists tend
to recommend chemotherapy before knowing the Recur-
rence Score results (due to high baseline risk for recurrence
in younger patients overall), but given the opportunity to
individualize treatment decisions, are likely to treat
Table 5 Odds ratios for receiving chemotherapy (logistic regression analysis on each age group)
Effecta Odds
ratio




95 % Wald confidence
limits
P value
Patients aged 40–55 years Patients aged [55 years
Oncotype DX testing (vs. no testing) 0.067 0.03–0.15 <0.0001 0.24 0.15–0.39 <0.0001
Tumor size
1–2 vs. \1 cm 0.26 0.068–0.97 0.046 0.56 0.28–1.12 0.10
[2 vs. \1 cm 0.52 0.14–1.94 0.33 0.73 0.36–1.46 0.37
[2 vs. 1–2 cm 2.03 0.98–4.21 0.056 1.29 0.85–1.97 0.23
Tumor grade
Grade 2 vs. 1 2.40 0.94–6.12 0.067 1.50 0.84–2.67 0.17
Grade 3 vs. 1 5.08 1.58–16.27 0.0063 3.01 1.56–5.81 0.001
Grade 3 vs. 2 2.12 0.84–5.32 0.11 2.02 1.27–3.21 0.0031
Nodal status
1 positive node vs. micrometastases 1.66 0.69–3.96 0.26 1.75 0.99–3.11 0.055
2 positive nodes vs. micrometastases 1.33 0.44–4.04 0.61 2.18 1.15–4.15 0.017
3 positive nodes vs. micrometastases 4.19 0.70–24.88 0.12 8.15 3.38–19.67 <0.0001
2 vs. 1 positive nodes 0.80 0.31–2.07 0.65 1.24 0.77–2.00 0.37
3 vs. 1 positive nodes 2.53 0.46–13.99 0.29 4.65 2.16–10.01 <0.0001
3 vs. 2 positive nodes 3.14 0.51–19.56 0.22 3.74 1.65–8.45 0.0015
For the patients aged 40–55, 31 out of 312 patients were excluded from the analysis due to missing data; for the patients aged[55 years, 84 out
of 599 patients were excluded from the analysis due to missing data
a Interactions between Oncotype DX testing and each of the other covariates were found to be non-significant
Bold values represents statistically significant odds ratios
Breast Cancer Res Treat (2013) 140:83–92 89
123
patients with endocrine therapy alone if the Recurrence
Score result is low. Notably, these treatment patterns are
consistent with the recent St. Gallen consensus document
stating that chemotherapy is not necessarily mandated in
patients with ER?, HER2 negative disease with 1–3
positive nodes [1].
From a patient’s perspective, Oncotype DX testing may
prevent unnecessary chemotherapy and its associated tox-
icity, thereby affecting quality of life. Furthermore, 3
studies have recently demonstrated that patients report
significantly lower conflict about their treatment decision
and decreased situational anxiety after receiving their
Recurrence Score result [15, 27, 30].
Reducing the proportion of patients receiving chemo-
therapy has economic implications. In the ER? node-
negative BC population in Israel, Klang et al. [18] have
shown that Oncotype DX testing leads to reduced chemo-
therapy use, and estimated that Oncotype DX testing is
associated with a net gain of 0.170 quality-adjusted life
years (QALY) per patient (due to reducing disutility
associated with chemotherapy and cancer recurrence) and
that the cost-effectiveness ratio is $10,770 per QALY
gained. There have been very few studies assessing the
cost-effectiveness of Oncotype DX in the N? ER? BC
population. The only study published to date is a UK-based
analysis which showed that using Oncotype DX is likely to
be cost-effective versus current clinical practice in this
patient population [31]. As the current study shows sig-
nificant reductions in chemotherapy use in the
ER? N1? BC population, findings from a health eco-
nomic analysis may be consistent with those from the UK
study [31]. A formal assessment of the cost-effectiveness
of using Oncotype DX in the Israeli ER? N? BC popu-
lation is warranted and is currently being planned.
This study has several limitations. Most notably, the 2
patient groups were unbalanced with respect to baseline
characteristics. Patients in the Oncotype DX group had, on
average, smaller tumors, and the group had lower fre-
quencies of patients with grade 3 tumors and those with 1,
2, and 3 positive nodes compared with controls. These
differences probably stem from the discrepancy in the
period of diagnosis (most of the Oncotype DX patients
were diagnosed from 2008 onward, whereas most of the
controls were diagnosed prior to 2008), and may therefore
reflect earlier BC diagnosis in the Oncotype DX patients
due to advances in BC awareness and screening over time.
Since all of these characteristics impact chemotherapy use
(Oncotype DX patients had characteristics associated with
less chemotherapy use), we performed a multivariate
logistic regression analysis (adjusting for age, tumor size,
tumor grade, and nodal status) to assess the statistical
significance of the observed reduction in chemotherapy use
with Oncotype DX testing, and demonstrated that testing
was significantly associated with reduced odds of receiving
chemotherapy (after adjustment for these known imbal-
ances). Although such an analysis is unlikely to capture all
imbalances between the groups (i.e., factors not measured/
included in the logistic regression model such as PR sta-
tus), the calculated ORs strongly suggest that the observed
reduction in chemotherapy use in the Oncotype DX group
was statistically significant. Another limitation of this study
stemming from the aforementioned difference in the period
of diagnosis between the 2 groups is the potential shift in
adjuvant treatment recommendations for this patient pop-
ulation over time. In addition, there may have been
selection bias in the small proportion of control patients
who were diagnosed after 2008 (i.e., after Oncotype DX
was available in Israel for N? patients), as these could
represent a subgroup of patients for whom oncologists felt
that the clinicopathologic characteristics were enough to
recommend treatment without ordering Oncotype DX
testing. Notably, the logistic regression analysis would
have addressed this limitation to a large extent. Finally, the
sample size of some of the subgroups in the Oncotype DX
group (specifically, patients \40 years of age) was rela-
tively small and therefore no conclusions could be drawn
regarding these subgroups.
In summary, our study demonstrates that since becom-
ing available for N1? ER? BC patients in Israel in 2008,
Oncotype DX testing has caused a dramatic shift in the
treatment paradigm for this patient population. The eco-
nomic impact of this paradigm shift has yet to be evaluated.
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